RESUMEN
Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life, causing psychosocial distress, and creating an ongoing financial burden. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis that can significantly alter the course of the disease in a relatively short period of time. There is a need to review the recommended treatment guidelines for moderate- to-severe psoriasis and psoriatic arthritis as the perception and demands of patients are constantly changing. Real world experience with this class of drugs is expanding and more new biologics are becoming available.
Asunto(s)
Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Terapia Biológica , Factores Inmunológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Adalimumab , Alefacept , Anticuerpos Monoclonales Humanizados , Etanercept , Humanos , Inmunoglobulina G/uso terapéutico , Infliximab , Psoriasis/fisiopatología , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéuticoRESUMEN
While there are certain common features in taking a history and doing a physical examination, every health care specialty has its own approach to gathering information. Dermatology is no exception. The purpose of this article is to outline in some detail the history taking and the physical examination commonly used to make a dermatologic diagnosis.